Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Emergence of RAS Mutations in Metastatic Colorectal Cancer Patients Receiving Cetuximab Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03401957
Recruitment Status : Recruiting
First Posted : January 17, 2018
Last Update Posted : January 17, 2018
Sponsor:
Collaborators:
National Cheng-Kung University Hospital
Kaohsiung Medical University Chung-Ho Memorial Hospital
Taipei Veterans General Hospital, Taiwan
Cathay General Hospital
Information provided by (Responsible Party):
National Health Research Institutes, Taiwan

Tracking Information
First Submitted Date January 10, 2018
First Posted Date January 17, 2018
Last Update Posted Date January 17, 2018
Estimated Study Start Date January 2018
Estimated Primary Completion Date January 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: January 10, 2018)
Percentage of detected circulating DNA RAS mutations during 1st line cetuximab exposure. [ Time Frame: 9 months ]
Percentage of detected RAS mutations during cetuximab treatment.
Original Primary Outcome Measures Same as current
Change History No Changes Posted
Current Secondary Outcome Measures
 (submitted: January 10, 2018)
  • Time to onset of newly detected circulating DNA RAS mutation. [ Time Frame: 9 months ]
    Time duration between the start of cetuximab treatment and newly detection of RAS mutation.
  • Mutation load (percentage of detected mutated alleles) until disease progression. [ Time Frame: 9 months ]
    Percentage of detected mutated alleles at disease progression.
  • Percentage of detected RAS mutations at the time of progression. [ Time Frame: 9 months ]
    Percentage of detected RAS mutations at the time of progression.
  • Clinical response rate by the investigator's judgement based on RECIST criteria. [ Time Frame: 9 months ]
    Response rate of tumor after cetuximab treatment.
  • Resection rate of liver or lung metastases. [ Time Frame: 9 months ]
    Resection rates of metastases after cetuximab treatment.
  • Duration of treatment with cetuximab in 1st line treatment. [ Time Frame: 9 months ]
    Time duration of cetuximab as the 1st line treatment.
  • Total accumulated dosage of cetuximab in 1st line treatment. [ Time Frame: 9 months ]
    Total accumulated dosage of cetuximab in 1st line treatment.
  • Progression-free survival from start of 1st line treatment with cetuximab. [ Time Frame: 9 months ]
    The time duration of subjects between the inclusion in the study and disease progression.
  • Overall survival from the start of 1st line treatment with cetuximab. [ Time Frame: 24 months ]
    The time duration of subjects between the inclusion in the study and death.
Original Secondary Outcome Measures Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title The Emergence of RAS Mutations in Metastatic Colorectal Cancer Patients Receiving Cetuximab Treatment
Official Title A Non-interventional Uncontrolled Multicenter Study to Investigate the Emergence of RAS Resistance Mutations in RAS Wild Type mCRC Patients Receiving First Line Cetuximab Treatment
Brief Summary To evaluate the emergence of RAS mutation in patients with metastatic colorectal cancer, circulating free DNA will be analyzed using mass spectrometric genotyping in subjects during cetuximab treatment. The hypothesis of this study is that acquired RAS mutation is responsible for the resistance to cetuximab treatment in wild-type colorectal cancer. The usefulness of liquid biopsy to monitor dynamic genetic alterations in colorectal cancer during treatment will also be investigated in this study.
Detailed Description

This is a single arm, non-interventional, uncontrolled, multicenter study in metastatic colorectal cancer patients receiving cetuximab-based infusional 5-FU regimen as 1st line treatment. Patients who are pathologically diagnosed as metastatic colorectal cancer with RAS wild type genotyping will be recruited in this study. Patients enrolled will be those for whom it is planned to treat their colorectal cancer with a cetuximab-based infusional 5-FU regimen according to the locally approved label. Cetuximab-based treatment is anticipated to be continued until disease progression, intolerable toxic effects, or withdrawal of consent occurs. Blood samples from patients enrolled in this study will be collected before the start of cetuximab-based chemotherapy, and every 3 months during the 1st line treatment with the cetuximab-based regimen. Blood sampling is also required at 2-3 weeks after disease progression following cetuximab treatment and after disease progression on 2nd line treatment. The blood samples will be sent to a central laboratory at the Taipei Institute of Pathology and evaluated for RAS genotype, using MassARRAY technique. The objectives of this study are described as follows.

Primary objective:

To observe the percentage of detected RAS mutations (circulating DNA) during 1st line cetuximab exposure in Taiwanese patients.

Secondary objective:

  1. To observe the time to onset of detected RAS mutation in circulating DNA.
  2. To observe the quantification mutation load change under treatment.
  3. To evaluate clinical response and resection rate of metastases with 1st line cetuximab exposure.
  4. To evaluate treatment duration with 1st line cetuximab.
  5. To investigate the correlation between the occurrence and levels of acquired RAS mutations post-cetuximab treatment and clinical outcomes (progression free survival and overall survival).
  6. To calculate total 1st line cetuximab exposure dosage.
  7. To investigate correlation between the irinotecan or oxaliplatin dosage and acquired resistance.
Study Type Observational [Patient Registry]
Study Design Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration 18 Months
Biospecimen Not Provided
Sampling Method Probability Sample
Study Population Patients with RAS wild-type metastatic colorectal cancer receiving cetuximab-based regimen (5-FU containing) as the 1st line treatment.
Condition
  • Colorectal Cancer
  • Drug Resistance
  • Mass Spectrometry
  • RAS-RAF Pathway Deregulation
Intervention
  • Drug: Cetuximab
    Cetuximab-based infusional 5-FU regimen as the 1st line treatment.
    Other Name: erbitux
  • Diagnostic Test: liquid biopsy
    The blood samples taken from subjects will be evaluated for RAS genotype using MassARRAY technique.
Study Groups/Cohorts RAS wild-type colorectal cancer
RAS mutation of patients who are pathologically diagnosed as metastatic colorectal cancer with RAS wild type genotyping will be evaluated using liquid biopsy during cetuximab treatment.
Interventions:
  • Drug: Cetuximab
  • Diagnostic Test: liquid biopsy
Publications * Chen SH, Tsai HL, Jiang JK, Sung YC, Huang CW, Yeh YM, Chen LT, Wang JY. Emergence of RAS mutations in patients with metastatic colorectal cancer receiving cetuximab-based treatment: a study protocol. BMC Cancer. 2019 Jun 28;19(1):640. doi: 10.1186/s12885-019-5826-7.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Recruiting
Estimated Enrollment
 (submitted: January 10, 2018)
120
Original Estimated Enrollment Same as current
Estimated Study Completion Date January 2022
Estimated Primary Completion Date January 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  1. Patients with histologically proven metastatic colorectal cancer for whom treatment with cetuximab in 1st line setting, is planned as part of routine clinical practice, as per the locally approved label and the best scientific information; the decision to prescribe cetuximab is at the sole discretion of the investigator. The choice of standard chemotherapy regimen for 1st line treatment of colorectal cancer is also at the sole discretion of the Investigator, based upon routine clinical practice.
  2. Patients aged 20 years and above.
  3. Patients who are molecularly diagnosed as having RAS wild-type mCRC.
  4. Patients who are willing to provide blood samples during the study
  5. Patients who are willing, and able and give, signed informed consent.

Exclusion Criteria:

  1. Patients having a history of prior exposure to any anti-EGFR therapy.
  2. Contra-indications to cetuximab as per locally approved label.
Sex/Gender
Sexes Eligible for Study: All
Ages 20 Years to 90 Years   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts
Contact: Shang Hung Chen, M.D. +886-6-7000123 ext 65113 bryanchen@nhri.org.tw
Listed Location Countries Taiwan
Removed Location Countries  
 
Administrative Information
NCT Number NCT03401957
Other Study ID Numbers EC1060904
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement Not Provided
Responsible Party National Health Research Institutes, Taiwan
Study Sponsor National Health Research Institutes, Taiwan
Collaborators
  • National Cheng-Kung University Hospital
  • Kaohsiung Medical University Chung-Ho Memorial Hospital
  • Taipei Veterans General Hospital, Taiwan
  • Cathay General Hospital
Investigators
Principal Investigator: Li-Tzong Chen, M.D. National Institute of Cancer Research, National Health Research Institutes
PRS Account National Health Research Institutes, Taiwan
Verification Date January 2018